| BIONTECH SE SPON. ADRS 1 |
| USA |
| Gesundheit |
| US09075V1026 / A2PSR2 |
| 22UA (Frankfurt) / BNTX (NASDAQ) |
| FRA:22UA, ETR:22UA, 22UA:GR, NASDAQ:BNTX |
| - |
| https://biontech.de/ |
|
BioNTech SE is a biotechnology company focused on the development of immunotherapies and mRNA-based medicines for cancer and infectious diseases. The company’s current portfolio includes oncology programs such as personalized and off-the-shelf canc..
>Volltext.. |
| 19793.34 Mio. EUR |
| 5516.04 Mio. EUR |
| 2822.5 Mio. EUR |
| -331.88 Mio. EUR |
| -1252.65 Mio. EUR |
| -5.08 EUR |
| 301.61 Mio. EUR |
| 9900.22 Mio. EUR |
| 731.12 Mio. EUR |
| 8.29 |
| 10.01% |
| -78.26% |
| - |
| - |
| - |
| 02.06.22 - 1.8290012€ |
| - |
| BIONTECH |
| 13.06.26 |
|